Stanley Durrleman
About Stanley Durrleman
Stanley Durrleman is an Inria Researcher at ICM with over a decade of experience in neuroinformatics and bioinformatics. He has a strong commitment to enhancing patient outcomes in neurodegenerative diseases through research and innovation.
Work at Inria
Stanley Durrleman has been working at Inria as a researcher since 2011. His role is based at the Institute of Brain and Spine (ICM) in the Paris Area, France. His research focuses on neuroinformatics, where he applies his expertise in statistical models to address challenges in neurodegenerative diseases. Durrleman's work aims to enhance patient care by providing insights that support informed decision-making for patients and healthcare teams.
Previous Roles at ICM - Brain & Spine Institute
From 2017 to 2021, Durrleman held two significant positions at the ICM - Brain & Spine Institute in the Paris Area. He served as the Coordinator of the Center of Neuroinformatics and as the Scientific Director of the bioinformatics and bio-statistics platform. In these roles, he contributed to the development of innovative approaches in neuroinformatics and bio-statistics, focusing on improving research and patient care in neurodegenerative diseases.
Education and Expertise
Durrleman has a strong educational background in mathematics, computer vision, and statistical learning. He earned a Master's degree from École Normale Supérieure Paris-Saclay in 2005 and another Master's degree in Electrical Engineering from Télécom Paris in 2006. He completed his Bachelor's degree in Applied Mathematics at École Polytechnique in 2004. His academic training laid the foundation for his research in neuroinformatics and bio-statistics.
Postdoctoral Experience
Before joining Inria, Stanley Durrleman was a Postdoctoral Fellow at the University of Utah from 2010 to 2011. This position allowed him to further develop his research skills and expertise in the field of neuroinformatics, contributing to his later work at Inria and ICM.
Research Contributions and Goals
Durrleman has been involved in inventing and patenting statistical models aimed at forecasting the progression of neurodegenerative diseases. His research is driven by the goal of empowering patients and care teams with timely information, thereby improving patient outcomes. He emphasizes the importance of the relationship between advancing research and enhancing patient care, and he supports drug developers in identifying optimal testing times for new treatments.